AUTHOR=Wang Run-Jie , Ke Rui-Quan , Yu Yi-Feng , Lu Guan-Zhong , Wu San-Gang 

TITLE=Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1366853

DOI=10.3389/fphar.2024.1366853

ISSN=1663-9812

ABSTRACT=<sec><title>Purpose:</title><p>To investigate the survival outcomes and toxicities associated with the addition of nimotuzumab to concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LANPC) patients who received induction chemotherapy (IC).</p></sec><sec><title>Methods:</title><p>Patients with stage III-IVA nasopharyngeal carcinoma who received IC and CCRT between January 2017 and October 2021 were retrospectively included. We aimed to compare the locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) between patients treated with CCRT+nimotuzumab and CCRT alone.</p></sec><sec><title>Results:</title><p>We included 411 patients in the analysis. Of these patients, 267 (65.0%) and 144 (35.0%) had CCRT+nimotuzumab and CCRT alone, respectively. Similar LRFS was found between those with and without nimotuzumab (92.9% vs. 92.6%, <italic>p</italic> = 0.855). The 3-year DMFS was 88.2% and 76.2% in those with and without nimotuzumab (<italic>p</italic> = 0.002). The 3-year DFS was 83.4% and 70.6% in those with and without nimotuzumab treatment (<italic>p</italic> = 0.003). The 3-year OS was 92.1% and 81.1% in those with and without nimotuzumab (<italic>p</italic> = 0.003). The multivariate Cox regression analysis indicated that the addition of nimotuzumab was independently associated with better DMFS (hazard ratio [HR] 0.606, <italic>p</italic> = 0.049), DFS (HR 0.613, <italic>p</italic> = 0.028), and OS (HR 0.497, <italic>p</italic> = 0.019). No significant differences in major toxicities were found between the two treatment arms, including hematologic toxicities, hepatoxicity, nephrotoxicity, gastrointestinal reactions, and mucositis (all <italic>p</italic> &gt; 0.05).</p></sec><sec><title>Conclusion:</title><p>The addition of nimotuzumab to CCRT after IC in LANPC has shown promising results in improving treatment outcomes and acceptable toxicities.</p></sec>